Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJ-MSCs and ECM Patch in Ischemic Cardiomyopathy
NCT04011059Phase 2Unknown
- Sponsor
- Hospital San Vicente Fundación
- Start
- Jul 2019
- Primary completion
- Jan 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of wharton's jelly-derived mesenchymal stem cells in ischemic cardiomyopathy (ICM), myocardial infarction (MI), sponsored by Hospital San Vicente Fundación. Status: unknown.
02
Drugs
wharton's jelly-derived mesenchymal stem cells
03
Conditions
ischemic cardiomyopathy (ICM)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT04011059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04011059.